CN106620667A - L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof - Google Patents
L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof Download PDFInfo
- Publication number
- CN106620667A CN106620667A CN201611157732.7A CN201611157732A CN106620667A CN 106620667 A CN106620667 A CN 106620667A CN 201611157732 A CN201611157732 A CN 201611157732A CN 106620667 A CN106620667 A CN 106620667A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- reducing
- lipid
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- -1 L-carnitine compound Chemical class 0.000 title abstract 5
- 239000004519 grease Substances 0.000 title abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 244000068988 Glycine max Species 0.000 claims abstract description 13
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 13
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 13
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 13
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 13
- 229960003624 creatine Drugs 0.000 claims abstract description 13
- 239000006046 creatine Substances 0.000 claims abstract description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 241001092040 Crataegus Species 0.000 claims description 12
- 235000008706 Ilex latifolia Nutrition 0.000 claims description 12
- 244000078118 Ilex latifolia Species 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 241000209035 Ilex Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical group C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical group C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an L-carnitine compound having effects of losing weight and reducing grease and a preparation method thereof. The L-carnitine compound is prepared from the following formula components in parts by weight: 15-25 parts of lotus leaves, 5-7 parts of L-carnitine, 6-8 parts of glutamine, 3-5 parts of fatty acid, 5-7 parts of soybean peptide, 5-7 parts of creatine, 5-7 parts of broadleaf holly leaves, 6-8 parts of rhizoma alismatis, 5-7 parts of triacylglycerol enzyme, 4-6 parts of amylopsin, 10-20 parts of hawthorn and 2-3 parts of salt. The L-carnitine compound is beneficial to the reduction of redundant fat in body. The L-carnitine compound can accelerate the decomposition of fat in body and the conversion of fat into energy and meanwhile can restrain the absorption of body for fat and saccharides, so that the dual-purpose of natural control and weight losing can be achieved.
Description
Technical field
The present invention relates to natural products drug world, combines in particular to a kind of l-cn of Weight-reducing and lipid-lowering effect
And preparation method thereof.
Background technology
Obesity refers to that feed heat exceedes human consumption amount and with storage as fat in internal, causes body weight to be above standard
A kind of physiological phenomenon.It is fat with angiocardiopathy, type ii diabetes, hypertension, dyslipidemia, hyperuricemia, some swell
Various diseases such as knurl and sleep disordered breathing are closely related.1997 the World Health Organization (WHO) announce that obesity is one
Plant disease.WHO thinks that obesity is listed as the great society problem of the world four with AIDS, drug and alcohol abuse.Medical circle also with fertilizer
Fat relevant coronary heart disease, hypertension, hyperlipidemia, diabetes, cerebrovas-cularaccident are referred to as " dead quintet ".The preventing and treating of science and
Improve the social concern that obesity symptom has become common concern in world wide.
The content of the invention
The invention provides l-cn combination of a kind of Weight-reducing and lipid-lowering effect and preparation method thereof, the present invention contributes to subtracting
Few fat unnecessary in vivo.Said composition can accelerate decomposition fatty in body and be converted into energy, while suppressing body to fat
The absorption of fat and carbohydrate, so as to reaching natural contral and lowering the purpose of body weight.
For achieving the above object, the present invention provides following technical scheme：
L-cn combination of a kind of Weight-reducing and lipid-lowering effect and preparation method thereof, by following mass fraction formula components group
Into：Lotus leaf 15-25 parts, l-cn 5-7 parts, glutamine 6-8 parts, aliphatic acid 3-5 parts, Soybean Peptide 5-7 part, creatine 5-7 parts,
Ilex Latifolia Thunb 5-7 parts, rhizoma alismatis 6-8 parts, triglyceride enzyme 5-7 parts, amylopsin 4-6 parts, hawthorn 10-20 parts, salt 2-3 parts.
Further：It is made up of following mass fraction formula components：15 parts of lotus leaf, 5 parts of l-cn, 6 parts of glutamine, fat
3 parts of fat acid, 5 parts of Soybean Peptide, 5 parts of creatine, 5 parts of Ilex Latifolia Thunb, 6 parts of rhizoma alismatis, 5 parts of triglyceride enzyme, 4 parts of amylopsin, hawthorn
10 parts, 2 parts of salt.
Further：It is made up of following mass fraction formula components：20 parts of lotus leaf, 6 parts of l-cn, 7 parts of glutamine, fat
4 parts of fat acid, 6 parts of Soybean Peptide, 6 parts of creatine, 6 parts of Ilex Latifolia Thunb, 7 parts of rhizoma alismatis, 6 parts of triglyceride enzyme, 5 parts of amylopsin, hawthorn
15 parts, 2.5 parts of salt.
Further：It is made up of following mass fraction formula components：25 parts of lotus leaf, 7 parts of l-cn, 8 parts of glutamine, fat
5 parts of fat acid, 7 parts of Soybean Peptide, 7 parts of creatine, 7 parts of Ilex Latifolia Thunb, 8 parts of rhizoma alismatis, 7 parts of triglyceride enzyme, 6 parts of amylopsin, hawthorn
20 parts, 3 parts of salt.
Further：Preparation method of the present invention has following steps：
Step one, each raw material weighed in the l-cn composition, pulverize and sieve, standby；
Step 2, weigh the pharmaceutically acceptable excipient, by the excipient and each raw material described in step one according to
After the equivalent method of progressively increasing is well mixed, the l-cn preparation is prepared.
The invention has the beneficial effects as follows：
1st, the present invention contributes to reducing fat unnecessary in vivo；
2nd, said composition can accelerate decomposition fatty in body and be converted into energy, while suppressing body to fat and sugar class
Absorption, so as to reaching natural contral and lowering the purpose of body weight.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment one：
A kind of l-cn combination of Weight-reducing and lipid-lowering effect is made up of following mass fraction formula components：Lotus leaf 15-25 parts,
L-cn 5-7 parts, glutamine 6-8 parts, aliphatic acid 3-5 parts, Soybean Peptide 5-7 part, creatine 5-7 parts, Ilex Latifolia Thunb 5-7 parts, pool
Rush down 6-8 parts, triglyceride enzyme 5-7 parts, amylopsin 4-6 parts, hawthorn 10-20 parts, salt 2-3 parts.
Embodiment two：
A kind of l-cn combination of Weight-reducing and lipid-lowering effect is made up of following mass fraction formula components：15 parts of lotus leaf, a left side
5 parts of carnitine of rotation, 6 parts of glutamine, 3 parts of aliphatic acid, 5 parts of Soybean Peptide, 5 parts of creatine, 5 parts of Ilex Latifolia Thunb, 6 parts of rhizoma alismatis, three acyls are sweet
5 parts of oily enzyme, 4 parts of amylopsin, 10 parts of hawthorn, 2 parts of salt.
Embodiment three：
A kind of l-cn combination of Weight-reducing and lipid-lowering effect is made up of following mass fraction formula components：20 parts of lotus leaf, a left side
6 parts of carnitine of rotation, 7 parts of glutamine, 4 parts of aliphatic acid, 6 parts of Soybean Peptide, 6 parts of creatine, 6 parts of Ilex Latifolia Thunb, 7 parts of rhizoma alismatis, three acyls are sweet
6 parts of oily enzyme, 5 parts of amylopsin, 15 parts of hawthorn, 2.5 parts of salt.
Example IV：
A kind of l-cn combination of Weight-reducing and lipid-lowering effect is made up of following mass fraction formula components：25 parts of lotus leaf, a left side
7 parts of carnitine of rotation, 8 parts of glutamine, 5 parts of aliphatic acid, 7 parts of Soybean Peptide, 7 parts of creatine, 7 parts of Ilex Latifolia Thunb, 8 parts of rhizoma alismatis, three acyls are sweet
7 parts of oily enzyme, 6 parts of amylopsin, 20 parts of hawthorn, 3 parts of salt.
Embodiment five：
A kind of preparation method preparation method of the l-cn combination of Weight-reducing and lipid-lowering effect comprises the steps：
Step one, each raw material weighed in the l-cn composition, pulverize and sieve, standby；
Step 2, weigh the pharmaceutically acceptable excipient, by the excipient and each raw material described in step one according to
After the equivalent method of progressively increasing is well mixed, the l-cn preparation is prepared.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. the l-cn combination of a kind of Weight-reducing and lipid-lowering effect, it is characterised in that：It is made up of following mass fraction formula components：
Lotus leaf 15-25 parts, l-cn 5-7 parts, glutamine 6-8 parts, aliphatic acid 3-5 parts, Soybean Peptide 5-7 part, creatine 5-7
Part, Ilex Latifolia Thunb 5-7 parts, rhizoma alismatis 6-8 parts, triglyceride enzyme 5-7 parts, amylopsin 4-6 parts, hawthorn 10-20 parts, salt 2-3 parts.
2. the l-cn combination of a kind of Weight-reducing and lipid-lowering effect according to claim 1, it is characterised in that：By following quality
Number formula components are constituted：
15 parts of lotus leaf, 5 parts of l-cn, 6 parts of glutamine, 3 parts of aliphatic acid, 5 parts of Soybean Peptide, 5 parts of creatine, 5 parts of Ilex Latifolia Thunb, pool
Rush down 6 parts, 5 parts of triglyceride enzyme, 4 parts of amylopsin, 10 parts of hawthorn, 2 parts of salt.
3. the l-cn combination of a kind of Weight-reducing and lipid-lowering effect according to claim 1, it is characterised in that：By following quality
Number formula components are constituted：
20 parts of lotus leaf, 6 parts of l-cn, 7 parts of glutamine, 4 parts of aliphatic acid, 6 parts of Soybean Peptide, 6 parts of creatine, 6 parts of Ilex Latifolia Thunb, pool
Rush down 7 parts, 6 parts of triglyceride enzyme, 5 parts of amylopsin, 15 parts of hawthorn, 2.5 parts of salt.
4. the l-cn combination of a kind of Weight-reducing and lipid-lowering effect according to claim 1, it is characterised in that：By following quality
Number formula components are constituted：
25 parts of lotus leaf, 7 parts of l-cn, 8 parts of glutamine, 5 parts of aliphatic acid, 7 parts of Soybean Peptide, 7 parts of creatine, 7 parts of Ilex Latifolia Thunb, pool
Rush down 8 parts, 7 parts of triglyceride enzyme, 6 parts of amylopsin, 20 parts of hawthorn, 3 parts of salt.
5. the preparation method that a kind of a kind of l-cn of Weight-reducing and lipid-lowering effect according to claim 1 is combined, its feature
It is：Comprise the steps：
Step one, each raw material weighed in the l-cn composition, pulverize and sieve, standby；
Step 2, the pharmaceutically acceptable excipient is weighed, by the excipient and each raw material described in step one according to equivalent
After the method for progressively increasing is well mixed, the l-cn preparation is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611157732.7A CN106620667A (en) | 2016-12-15 | 2016-12-15 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611157732.7A CN106620667A (en) | 2016-12-15 | 2016-12-15 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620667A true CN106620667A (en) | 2017-05-10 |
Family
ID=58822662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611157732.7A Pending CN106620667A (en) | 2016-12-15 | 2016-12-15 | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620667A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109363163A (en) * | 2018-11-21 | 2019-02-22 | 苏州衍生生物科技有限公司 | A kind of health food and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030005086A (en) * | 2002-11-08 | 2003-01-15 | 주식회사 이롬라이프 | Diet composition containing freeze-dried uncooked food and dietary fiber |
| CN102512655A (en) * | 2011-11-30 | 2012-06-27 | 北京康比特体育科技股份有限公司 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
| CN103055057A (en) * | 2012-08-31 | 2013-04-24 | 中国科学院生物物理研究所 | Plant weight-losing and fat-reducing composite compatible to L-carnitine |
-
2016
- 2016-12-15 CN CN201611157732.7A patent/CN106620667A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030005086A (en) * | 2002-11-08 | 2003-01-15 | 주식회사 이롬라이프 | Diet composition containing freeze-dried uncooked food and dietary fiber |
| CN102512655A (en) * | 2011-11-30 | 2012-06-27 | 北京康比特体育科技股份有限公司 | L-carnitine composition, L-carnitine preparation and preparation method and application thereof |
| CN103055057A (en) * | 2012-08-31 | 2013-04-24 | 中国科学院生物物理研究所 | Plant weight-losing and fat-reducing composite compatible to L-carnitine |
Non-Patent Citations (2)
| Title |
|---|
| 熊昌云 等: ""普洱茶不同溶剂提取组分降脂减肥作用的比较研究"", 《茶业科学》 * |
| 范轶欧 等: ""左旋肉碱、茶多酚和魔芋粉复合物安全性评价及其减肥效果研究"", 《毒理学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109363163A (en) * | 2018-11-21 | 2019-02-22 | 苏州衍生生物科技有限公司 | A kind of health food and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103055057B (en) | Plant weight-losing and fat-reducing composite compatible to L-carnitine | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| CN103349323A (en) | Radix puerariae anti-alcoholism beverage recipe | |
| CN105727081A (en) | Healthcare product composition for treating gout | |
| CN102732412A (en) | Production process of vinegar-soaked black beans, and produced black bean vinegar and vinegar-soaked black beans | |
| CN105028868A (en) | Black garlic, black onion and black soybean peptide chewable tablet and preparation method thereof | |
| CN103181552A (en) | Health care food for regulating blood lipid and preparation method thereof | |
| CN1857475A (en) | Composition for preventing and treating cardias and cerebral vascular diseases and its application | |
| CN101019895B (en) | Health product for reducing blood sugar and its prepn | |
| CN101940319A (en) | Novel health care product with effects of reducing weight, lowering blood fat, expelling toxin and beautifying | |
| CN106620667A (en) | L-carnitine compound having effects of losing weight and reducing grease and preparation method thereof | |
| CN105770715A (en) | Composition with blood sugar lowering function, and preparation method thereof | |
| CN103349051A (en) | Biscuits suitable for hyperlipoidemia crowd | |
| CN101129147A (en) | Coix seed milk | |
| CN101433629A (en) | Chinese medicinal composition with function for reducing blood fat and preparation method thereof | |
| CN103463407A (en) | Body regulating and blood sugar reducing capsule | |
| CN106867859A (en) | Health-care vinegar | |
| CN100473415C (en) | Health-care product for treating cardiovascular and cerebralvascular disease | |
| CN101862442A (en) | Cough-relieving Chinese medicinal composition and preparation method thereof | |
| CN116114887A (en) | Composite double-protein composition and preparation method thereof | |
| CN102499366A (en) | Health-care food for adjusting blood fat and preventing fatigue | |
| CN102366098A (en) | Supercritical propolis soft capsules and preparation method thereof | |
| CN106867857A (en) | Herbal health care vinegar with immunological regulation effect | |
| CN105410908B (en) | Composition for dietotherapy Weight-reducing and lipid-lowering and preparation method thereof | |
| CN104140921A (en) | Health-care vinegar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |
|
| WD01 | Invention patent application deemed withdrawn after publication |